Thyroid disorders — Hashimoto's thyroiditis, hyperthyroidism and hypothyroidism — are not absolute contraindications for dental implants, but they are relevant risk factors. The hormonal status at the time of implantation is decisive: well-controlled patients have comparable success rates to healthy individuals. Uncontrolled thyroid function increases the risk of osseointegration failure, prolonged healing and peri-implantitis. Digital CBCT diagnostics and precise bone planning are especially important for this patient group.
Thyroid disorders are among the most common endocrine conditions worldwide — in Austria alone, an estimated 800,000 people are affected, with women significantly more often than men. Many of these patients present with a desire for dental implants and ask whether their condition is an obstacle. The answer is nuanced: hormonal status, type of disorder and current medication determine the individual risk profile — not the diagnosis alone.
Thyroid and Bone Metabolism: The Direct Connection
Thyroid hormones (T3 and T4) are directly involved in bone metabolism. T3 stimulates both osteoclasts and osteoblasts — in hyperthyroidism, bone resorption predominates; in hypothyroidism, the entire bone remodelling process slows down. Both extremes impair implant osseointegration, albeit through different mechanisms.
| Condition | Bone Effect | Implant Risk | Controllable? |
|---|---|---|---|
| Hashimoto's thyroiditis | Hypothyroidism → slowed bone remodelling, reduced healing | Moderate — low with controlled TSH | Yes, via L-thyroxine |
| Hypothyroidism (non-Hashimoto) | As above, possible immunosuppression | Moderate | Yes, via hormone replacement |
| Hyperthyroidism (Graves' disease) | Increased bone resorption, osteoporosis risk | Elevated — especially uncontrolled | Yes, via antithyroid drugs or radioiodine |
| Subclinical hyperthyroidism | Mild bone loss, often asymptomatic | Low to moderate | Monitoring required |
Hashimoto's Thyroiditis: Special Considerations for Implant Patients
Hashimoto's is an autoimmune condition in which the immune system attacks thyroid tissue. For implant patients, two aspects are relevant: first, the resulting hypothyroidism with slowed bone remodelling; second, the chronic inflammatory readiness of the immune system. The latter increases the risk of peri-implant inflammation, even when TSH levels are well controlled.
A normal TSH value does not mean that autoimmune activity is controlled. Anti-TPO antibodies (thyroid peroxidase antibodies) may remain elevated and influence the local immune response in the jawbone. Before implantation, both TSH and anti-TPO titres should be known.
Hyperthyroidism and Graves' Disease: When Is Implantation Possible?
In active, uncontrolled hyperthyroidism, elective implantation is contraindicated. Elevated T3/T4 levels accelerate bone loss, increase bleeding risk through tachycardia and impair wound healing. After successful treatment — whether via antithyroid drugs, radioiodine therapy or thyroidectomy — and stable euthyroidism for at least 3–6 months, implantation is generally possible.
- TSH within normal range (0.4–4.0 mU/l) for at least 3 months
- No active antithyroid therapy with agranulocytosis risk (thiamazole, propylthiouracil)
- Cardiological clearance for known hyperthyroid cardiomyopathy
- CBCT to assess bone density before planning
Drug Interactions: L-Thyroxine, Thiamazole and Implantology
| Drug | Indication | Relevance for Implantology |
|---|---|---|
| L-Thyroxine (Levothyroxine) | Hypothyroidism, Hashimoto's | No direct risk. Overdose (TSH < 0.1) increases osteoporosis risk. |
| Thiamazole / Carbimazole | Hyperthyroidism, Graves' disease | Rare agranulocytosis → increased infection risk. Check blood count before surgery. |
| Propylthiouracil (PTU) | Hyperthyroidism (pregnancy) | As thiamazole, additionally hepatotoxicity possible. |
| Radioiodine therapy (aftercare) | Post-radioiodine hypothyroidism | No direct risk with controlled TSH. |
| Bisphosphonates (for osteoporosis) | Hyperthyroid-induced osteoporosis | Increased MRONJ risk (jaw necrosis). Separate risk assessment required. |
Digital Diagnostics and Planning for Thyroid Patients
Patients with thyroid disorders — particularly those with a history of hyperthyroidism or Hashimoto's with elevated antibodies — benefit especially from digital implant planning at the Institute for Implantology and Digital Dentistry Vienna. CBCT-based 3D bone analysis enables precise assessment of bone density and quality, which can vary greatly with thyroid-related bone loss.
- CBCT scan for 3D bone analysis (density, volume, trabecular structure)
- Digital risk classification: bone density score per Lekholm & Zarb
- Computer-guided implant positioning in optimal bone zones
- Guided surgery with drill guide for precise, atraumatic insertion
- Digital recall system with close monitoring intervals (3 instead of 6 months in year 1)
Conclusion: Thyroid Disease and Implants — No Contradiction with Proper Planning
Patients with Hashimoto's, hypothyroidism or treated hyperthyroidism can generally be successfully treated with dental implants — provided hormonal status is stable and planning accounts for the individual risk profile. Collaboration between implantologist and endocrinologist is not an optional extra, but medical standard.
Institut für Implantologie und digitale Zahnmedizin Wien
Fachärztliches Team IIDZ Wien
Weitere Artikel
Thematisch verwandt
Hinweis: Diese Inhalte dienen ausschließlich der allgemeinen Information und ersetzen keine individuelle zahnärztliche Beratung. Das Institut für Implantologie und digitale Zahnmedizin Wien ist eine gemeinnützige, unabhängige Wissenschaftsplattform — kein Behandlungsbetrieb. Alle Angaben entsprechen dem aktuellen Stand der wissenschaftlichen Literatur; individuelle Behandlungsentscheidungen müssen stets mit einem approbierten Zahnarzt oder Facharzt getroffen werden.